key: cord-0890603-n7m57d7c
authors: Wong, Kalai; Farooq Alam Shah, Mir Umer; Khurshid, Maman; Ullah, Irfan; Tahir, Muhammad Junaid; Yousaf, Zohaib
title: COVID-19 associated vasculitis: A systematic review of case reports and case series
date: 2022-01-13
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103249
sha: 20ced36823b649603b82129f44a7fc28aa69a11e
doc_id: 890603
cord_uid: n7m57d7c

Vasculitis is one of the complications of COVID-19. We conducted a systematic review analysing the association of COVID-19 with vasculitis. We searched Google Scholar and PubMed from December 1, 2019, to October 11, 2021. The review included 8 studies (7 case reports and 1 case series) reporting 9 cases of vasculitis secondary to COVID-19. The mean age was 29.17 ± 28.2 years, ranging from 6 months to 83 years. The male to female ratio was 4:5. Maculopapular, violaceous, papular and erythematous rash were common. Heparin(n = 2), corticosteroids (n = 6) (methylprednisolone) and intravenous immunoglobulin (n = 4) were prescribed in these patients. Significant clinical improvement was observed in 8 out of 9 patients. One person died during treatment. Our study discusses vasculitis as one of the complications of COVID-19. Furthermore, the pathophysiology, clinical presentation, and management of COVID-19 associated vasculitis is discussed.

With more than 241 million cases and 4.91 million deaths worldwide, coronavirus-2019 (COVID -19) has been a significant global economic and healthcare burden [1] . Several complications have been noted in patients of COVID-19. Vasculitis is the inflammation of blood vessels. It is triggered by autoimmune disorders, infections, and trauma [2] . There are different types of vasculitis, but leucocytoclastic (LCV), IgA, and Kawasaki disease like vasculitis are more commonly associated with COVID-19 patients.

IgA vasculitis (IgAV) is a systemic, immune complex-mediated, small-vessel vasculitis characterized by nonthrombocytopenic palpable purpura, arthritis, and abdominal pain. It typically occurs in children, although adults can also be a target of it. IgA vasculitis usually resolves spontaneously. Thus, only supportive treatment is advised [3] . Leukocytoclastic vasculitis, much like IgAV, is a small vessel vasculitis marked by immune complex-mediated damage. It appears as erythematous macules with palpable purpura appearing bilaterally on lower extremities and buttocks. However, unlike IgAV, it typically affects adults, although other groups are also at risk [4] . On the other hand, Kawasaki disease is a predominantly medium-vessel vasculitis that mainly affects children aged five years or younger. Patients typically present with fever, rash, and swollen hands and feet. If left untreated, it may cause heart complications and even death. Although reportedly globally, it has the highest incidence in Japan [5] . Medications commonly used to treat vasculitis include corticosteroids, immunosuppressive drugs, monoclonal antibodies, anticoagulants, anti-platelet agents, and immunoglobulin therapy. The choice of medications mainly depends on the type of vasculitis and the organ that is affected. As there is a rise in cases of COVID-19-associated vasculitis and vasculopathy, an effective treatment plan is yet to be discovered.

For over two years, varying complications of COVID-19 have been reported, and comprehensive systematic reviews of cases have come forth as a result [6, 7] . However, the topic of vasculitis secondary to COVID-19 has been relatively untouched. To the best of our knowledge, this is the first systematic review of case reports and case series on the occurrence of vasculitis in COVID-19 patients. This article reviewed the relationship between COVID-19 and vasculitis, collated evidence, and summarized available literature.

Our work was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-analyses(PRISMA) checklist (Supplementary file S1) [8] . We searched PubMed and Google scholar from December 1, 2019, to October 11, 2021, for studies published in English. Search terms were combined using appropriate Boolean operators. It included subject heading terms/ keywords relevant to COVID-19 (e.g., SARS-CoV-2 OR Coronavirus Disease 2019 OR COVID-19 OR severe acute respiratory syndrome coronavirus 2 OR coronavirus infection) and vasculitis (e.g., Vasculitis OR Vasculitides OR Angiitis). The references of selected studies were also checked to ensure completeness of the search. Please see Supplementary File S1 for a sample search strategy. Furthermore, our study was registered in International prospective register of systematic reviews (PROSPERO) and holds the unique identifying number (UIN); CRD42021296389 [9].

Only case reports, case series, correspondence articles, and editorials that reported individuallevel data on the emergence of vasculitis among COVID-19 positive patients were considered for this review. Studies were excluded if they did not present original empirical data on the clinical manifestation of the condition or reported aggregate-level data. The title, abstract, and full-text screening were completed in duplicate and independently by two reviewers (MUFAS and MK). Disagreements regarding the inclusion of studies for data extraction were resolved by the senior author (IU).

Duplicate studies were removed, whereafter data was extracted in case abstraction form on excel sheets. We collected data on age, gender, physical findings, type of vasculitis, treatment regimen, and treatment outcomes.

We used the Joanna Briggs institute's critical appraisal tools to assess the quality of included papers [10, 11] . Selected studies were examined for inclusion criteria, sample size, description of study participants and setting. Two reviewers independently assessed the methodological quality of each paper. Quality assessments were done with different tools based on different study designs. Each tool was modified to provide a numeric score. Tools had eight items for case reports and ten for case series. Included case reports (n=7) had a mean score of 6.71±0.45 with scores ranging from 6 to 7 [12, 13, [14] [15] [16] [17] [18] . Meanwhile, the case series by Akca et al. scored seven on a scale of 1 to 10 [19] . The detailed results of the quality assessment are provided in Supplementary file S1. The quality of our systematic review was assessed using AMSTAR 2 criteria [20] . The level of compliance with AMSTAR 2 came out to be "low". As only case reports were included in the analyses and the number of studies were less, we couldn't conduct a meta-analysis.

We reported descriptive data of COVID-19 positive patients presenting with vasculitis. The data was presented in a table describing the symptoms, treatment, and subsequent prognosis among nine individuals who suffered from the condition( Table 1 ). The median and interquartile range (IQR) of the continuous variable (age) was calculated.

Our initial search yielded 10552 results ( Figure 1 ). After removing duplicate studies (4223), titles and abstracts of the remaining studies were checked (6329). After excluding articles through title and abstract search (5987), full-text versions of the remaining articles were read (342). Studies were excluded if they were not in English (n=27), reported aggregate-level data (n=13), reported insufficient information on clinical events (n=38), or were not of the desired study type (e.g., case report and case series) (n=257). Finally, a total of 8 articles, comprising of 9 patients, met our inclusion criteria and were added to our qualitative analysis (Table 1) . Table 1 shows the information of 9 patients who developed vasculitis secondary to COVID-19. The median age of patients was 24 (49) years, ranging from 6 months to 83 years. The male to female ratio of patients was 4:5. Maculopapular, violaceous, papular, and erythematous rash were common presenting complaints. Other minor findings include arthralgia (n=2), periarticular swelling (n=1), lymphadenopathy (n=1) and abdominal pain (n=1). Although children did not complain of arthralgia, two adults presented with it. Common treatment regimen for patients with vasculitis secondary to COVID-19 included heparin(n=2), corticosteroid therapy (n=6) (methylprednisolone) and intravenous immunoglobulin (n=4). Although a 7-year-old died of hypoxia, an overall good prognosis was observed (88.89%). Significant clinical improvement was observed in 8 out of 9 patients. 2 patients each were prescribed steroids and aspirin post-discharge. . Accumulation of inflammatory cells and viral inclusions were identified within the endothelium. In autopsy and surgical tissue specimens, diffuse lymphocytic endotheliitis and apoptotic bodies were observed [23] . Thus, endotheliitis and endothelial cell injury can result in vasculitis amongst COVID-19 patients. Kawasaki disease (KD) is an acute inflammatory disease characterized by medium-sized vasculitis with a predilection for coronary arteries, predominantly affecting children <5 years of age [24] . The leading theory for the pathogenesis of KD is that an unknown infectious agent leads to activation of the immune system in a genetically susceptible child, which can J o u r n a l P r e -p r o o f be supported by the apparent seasonality of KD [25] . It begins with neutrophil infiltration of the arterial wall, destroying the vascular wall and causing aneurysms. This phase is followed by lymphocytic infiltration with CD8+T cells, plasma cells, and monocytes, releasing proinflammatory cytokines Interleukin 1 Beta (IL-1β) and Tumor nNcrosis Factor Alpha (TNFα), which may continue for months to years in a few patients (chronic arteritis) [26, 27] . As SARS-CoV-2 infection can accumulate inflammatory cells within the endothelium, endothelial inflammation, and dysfunction, it can trigger the development of KD. The systemic inflammatory response to pneumonia may potentiate the inflammatory response within coronary lesions, rendering endothelial dysfunction [23] , resulting in the development of KD. IgAV, formerly known as Henoch-Schönlein purpura (HSP), is a type of small-vessel vasculitis that is mediated by immune-complexes deposits containing IgA and is the most common form of systemic vasculitis in children [28] . The current etiopathogenetic hypothesis for IgAV assumes an abnormal immune response to various antigens in genetically susceptible individuals [29] . However, the exact etiology remains unknown. IgAV is usually preceded by upper respiratory tract infections, medications, vaccinations, or malignancies [30] . Thus, an upper respiratory tract infection by SARS-CoV-2 could be a triggering factor in the emergence of IgA vasculitis. It has been hypothesized that mucosal infections lead to upregulation of IL-6, which could lead to the development of Galactose Deficient IgA1 (Gd-IgA1) by altering glycosylation [31] . This variant of IgA1 antigenically recognizes structures of some microorganisms, anti-glycan IgA1 or Immunoglobulin G (IgG) antibodies, and forms circulating complexes, the deposition of these complexes can result in IgA vasculitis and nephritis. The cytokine storm and drugs are given during SARS-COV-2 infection could also be associated with COVID-19, resulting in IgA vasculitis. Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis characterized by immune complex-mediated inflammation of dermal capillaries and venules [4] . Although LCV is idiopathic in 50% of cases, it can also occur secondary to systemic autoimmune diseases, malignancies, drugs, and chronic infections. These factors induce immune complex deposition and complement-mediated damage within small vessels. Neutrophil chemotaxis followed by secondary exudation of fibrin, erythrocytes, and serum, injuring the vessel wall and causing fibrinoid necrosis. Elevated levels of serum IL-1, IL6, and IL-8 and tumor necrosis factors can also be detected [4] . Additionally, COVID-19 causes a cytokine storm linked with a rise in IL6 levels [16] . This rise in IL-6 levels and immune complex-mediated damage can result in inflammation of small vessels causing LSV.

The treatment for COVID-19 induced vasculitis should be curated according to the severity of vasculitis, type of vasculitis, and patient demographics. The disease self resolves in most cases, however, based on the severity of skin-limited IgA vasculitis (sparing GI and renal involvement) a symptomatic treatment plan should be devised. Analgesics like acetaminophen should be prescribed for joint pain and muscle pain. Compression therapy and antihistamines should be prescribed for cutaneous variant of IgA vasculitis. This could reduce the formation of new lesions by inhibiting vascular dilatation [32] . Antihistamines work by inhibiting vasodilation, thereby, reducing blood supply. This prevents entry of immunoglobin to the affected area. Steroids should be given if there is a chance of incipient necrosis, which otherwise would slow down the healing process [32] . In KD, treatment comprises of high dose IVIG and aspirin [5] . Combinational therapy of IVIG, TNF inhibitors, steroids, calcineurin inhibitors, or anakinra, might be helpful to treat patients with IVIG-resistant disease [5] . LCV is mild and resolves with supportive measures like leg elevation, rest, compression stockings, and antihistamines. A 4-6 week tapering dose of corticosteroids can be used in more chronic or resistant cases. Rarely, immunosuppressive steroid-sparing agents such as methotrexate, azathioprine, mycophenolate mofetil, dapsone, cyclophosphamide, and intravenous immunoglobulin may be needed [4] .

This article has some limitations. For example, not all case reports included the patient's past medical history and risk factors for COVID-19 associated vasculitis, which may contribute to the new onset of rash. Some of the vasculitis cases are in asymptomatic COVID-19 patients, which raises the question about the correlation between COVID-19 and vasculitis. More cases were reported in children and adolescents, so more investigations are needed in diverse populations.

COVID-19 associated vasculitis is rare and lacks a clear treatment protocol. Steroid have shown clinical benefits in case reports. More studies are needed to establish a definitive treatment protocol for COVID-19 associated vasculitis.

The authors have no competing interests to declare Funding source:

The authors have no funding source to declare

COVID-19) Dashboard [Internet]. World Health Organization

Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review

Leukocytoclastic Vasculitis

Treasure Island: StatPearls Publishing

Central Retinal Vein Occlusion in patients with COVID-19 infection: A systematic review

COVID-19-associated mucormycosis: Case report and systematic review

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

JBI Manual for Evidence Synthesis

Methodological quality of case series studies

Covid-19 related IgA vasculitis

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr

COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult

Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy

A child with covid-19 and immunoglobulin a vasculitis

Cutaneous small-vessel vasculitis secondary to COVID-19 infection: A case report. J Eur Acad Dermatology Venereol

Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatology Venereol

Kawasaki-like disease in children with COVID-19

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

COVID-19-associated vasculitis and vasculopathy

Endothelial cell infection and endotheliitis in COVID-19

Kawasaki Disease and COVID-19

Kawasaki Disease: an Update

Kawasaki disease: pathophysiology and insights from mouse models

Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study

e38998. Available from

Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins

Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study

Henoch-schönlein purpura: A literature review

New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)

IgA vasculitis

registry: PROSPERO 2. Unique Identifying number or registration ID

Hyperlink to your specific registration

The authors have no acknowledgements to disclose.

Provenance and peer review Not commissioned, externally peer-reviewed

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.The authors have no conflict of interests to declare.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.The authors have no funding source to declare.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.Since this is a review article no ethical approval was needed.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.Kalai Wong: study concept, study design, data collection, data analysis, data interpretation, writing the paper Mir Umer Farooq Alam Shah: study concept, data collection, data analysis, writing the paper Maman Khurshid: study concept, data collection, data analysis, writing the paper Irfan Ullah: study concept, data analysis, writing the paper Muhammad Junaid Tahir: study concept, data collection, data analysis, writing Zohaib Yousaf: study concept, data analysis, writing

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.